Biocell,
Journal Year:
2024,
Volume and Issue:
48(6), P. 905 - 922
Published: Jan. 1, 2024
Hepatocellular
carcinoma
(HCC)
remains
a
prevalent
and
challenging
malignancy
globally,
characterized
by
its
numerous
causal
factors
generally
unfavorable
prognosis.In
the
relentless
pursuit
of
effective
treatment
modalities,
natural
products
have
emerged
as
promising
relatively
non-toxic
alternative,
garnering
significant
interest.The
integration
with
contemporary
medical
research
has
yielded
encouraging
therapeutic
outcomes
in
management
HCC.This
review
offers
comprehensive
overview
underlying
HCC,
diverse
options
available,
highlights
advancements
made
anti-HCC
research.Particularly,
we
provide
an
outline
various
types
products,
their
corresponding
nomenclature,
target
molecules,
mechanisms
action
that
exhibit
activities.Natural
are
anticipated
to
play
pivotal
role
future
plans
for
liver
cancer,
potentially
offering
patients
improved
survival
rates
enhanced
quality
life.
Advanced Science,
Journal Year:
2023,
Volume and Issue:
10(33)
Published: Oct. 22, 2023
Hepatocellular
carcinoma
(HCC)
is
a
lethal
and
aggressive
human
malignancy.
The
present
study
examins
the
anti-tumor
effects
of
deubiquitylating
enzymes
(DUB)
inhibitors
in
HCC.
It
found
that
inhibitor
ubiquitin
specific
peptidase
8
(USP8)
DUB-IN-3
shows
most
effective
anti-cancer
responses.
Targeting
USP8
inhibits
proliferation
HCC
induces
cell
ferroptosis.
In
vivo
xenograft
metastasis
experiments
indicate
inhibition
suppresses
tumor
growth
lung
metastasis.
treatment
or
depletion
decrease
intracellular
cystine
levels
glutathione
biosynthesis
while
increasing
accumulation
reactive
oxygen
species
(ROS).
Mechanistical
studies
reveal
stabilizes
O-GlcNAc
transferase
(OGT)
via
inhibiting
K48-specific
poly-ubiquitination
process
on
OGT
protein
at
K117
site,
STE20-like
kinase
(SLK)-mediated
S716
phosphorylation
required
for
interaction
with
OGT.
Most
importantly,
O-GlcNAcylates
solute
carrier
family
7,
member
11
(SLC7A11)
Ser26
cells,
which
essential
SLC7A11
to
import
from
extracellular
environment.
Collectively,
this
demonstrates
pharmacological
knockout
can
inhibit
progression
induce
ferroptosis
decreasing
stability
OGT,
imposes
great
challenge
targeting
potential
approach
treatment.
Cancer Gene Therapy,
Journal Year:
2024,
Volume and Issue:
31(8), P. 1105 - 1112
Published: March 18, 2024
Abstract
Hepatocellular
Carcinoma
(HCC)
is
one
of
the
most
common
types
primary
liver
cancer.
Current
treatment
options
have
limited
efficacy
against
this
malignancy,
primarily
owing
to
difficulties
in
early
detection
and
inherent
resistance
existing
drugs.
Tumor
heterogeneity
a
pivotal
factor
contributing
significantly
recurrent
manifestations
HCC.
Intratumoral
an
important
aspect
spectrum
complex
tumor
contributes
late
diagnosis
failure.
Therefore,
it
crucial
thoroughly
understand
molecular
mechanisms
how
develops.
This
review
aims
summarize
possible
dimensions
with
emphasis
on
intratumoral
heterogeneity,
evaluate
its
profound
impact
therapeutic
strategies
for
HCC,
explore
suitability
appropriate
pre-clinical
models
that
can
be
used
best
study
heterogeneity;
thus,
opening
new
avenues
cancer
treatment.
Non-coding RNA Research,
Journal Year:
2024,
Volume and Issue:
9(2), P. 277 - 287
Published: Jan. 26, 2024
The
intricate
molecular
landscape
of
cancer
pathogenesis
continues
to
captivate
researchers
worldwide,
with
Circular
RNAs
(circRNAs)
emerging
as
pivotal
players
in
the
dynamic
regulation
biological
functions.
study
investigates
elusive
link
between
circRNAs
and
Transforming
Growth
Factor-β
(TGF-β)
signalling
pathway,
exploring
their
collective
influence
on
progression
metastasis.
Our
comprehensive
investigation
begins
by
profiling
circRNA
expression
patterns
diverse
types,
revealing
a
repertoire
intricately
linked
TGF-β
pathway.
Through
integrated
bioinformatics
analyses
functional
experiments,
we
elucidate
specific
circRNA-mRNA
interactions
that
modulate
signalling,
unveiling
regulatory
controls
governing
this
crucial
Furthermore,
provide
compelling
evidence
impact
circRNA-mediated
modulation
key
cellular
processes,
including
epithelial-mesenchymal
transition
(EMT),
migration,
cell
proliferation.
In
addition
mechanistic
roles,
have
shown
promise
diagnostic
prognostic
biomarkers,
well
potential
targets
for
therapy.
Their
ability
critical
pathways,
such
axis,
underscores
significance
biology
clinical
applications.
interplay
is
dissected,
uncovering
novel
circuits
contribute
complexity
biology.
This
review
unravels
previously
unexplored
dimension
carcinogenesis,
emphasizing
role
shaping
landscape.
Cells,
Journal Year:
2025,
Volume and Issue:
14(4), P. 253 - 253
Published: Feb. 11, 2025
Hepatocellular
carcinoma
(HCC)
poses
a
substantial
global
health
burden,
with
poor
prognosis
and
high
mortality
rates.
Dysregulated
lipid
metabolism
has
emerged
as
critical
driver
of
HCC
progression.
While
mTORC1
signaling
is
known
to
promote
synthesis
in
HCC,
the
regulatory
mechanisms
governing
remain
largely
unclear.
Here,
we
demonstrate
that
inhibition
significantly
reduces
lipogenesis
uncover
axis
involving
transcription
factor
ATF3
leucine–arginine
transporter
SLC7A7.
Transcriptomic
analysis
patients
reveals
an
inverse
correlation
between
expression
synthesis,
finding
corroborated
by
experimental
validation.
Mechanistically,
suppresses
signaling,
thereby
inhibiting
biosynthesis,
SLC7A7
identified
key
intermediary
this
process.
Specifically,
binds
enhancer
region
SLC7A7,
driving
its
transcriptional
activation
subsequently
restraining
activity.
Functional
assays
ATF3-overexpressing
-knockdown
cell
lines
further
confirm
ATF3′s
role
tumor
suppressor.
Our
study
identifies
novel
ATF3-SLC7A7-mTORC1
attenuates
tumorigenesis
establishing
link
hepatocarcinogenesis.
These
findings
offer
new
insights
into
potential
therapeutic
targets
for
treatment
HCC.
Discover Oncology,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: Feb. 15, 2025
Disulfidptosis,
a
recently
identified
cell
death
mechanism,
plays
pivotal
role
in
the
development,
progression,
and
treatment
of
digestive
tract
tumors,
including
gastric
cancer,
hepatocellular
esophageal
colorectal
pancreatic
cholangiocarcinoma,
neuroendocrine
which
have
high
global
incidence
mortality
rates.
Analyzing
expression
disulfidptosis-related
gene
within
tumor
microenvironment
enhances
our
understanding
biology
facilitates
novel
diagnostic
therapeutic
strategies.
Research
on
immune
infiltration
checkpoints
can
identify
targets
linked
to
disulfidptosis,
thereby
improving
immunotherapy
efficacy.
Targeting
genes
such
as
SLC7A11,
are
essential
for
maintaining
glutathione
levels
regulating
oxidative
stress,
may
overcome
chemoresistance
enhance
existing
treatments.
Disulfidptosis
could
complement
current
therapies
it
induces
cytoskeletal
collapse
selective
death,
especially
chemoresistant
cancers.
Additionally,
like
RPN1,
NCKAP1
cancer
correlate
with
poor
prognosis,
highlighting
their
potential
prognostic
biomarkers.
Personalized
medicine
approaches
utilizing
biomarkers
patients
who
would
benefit
from
targeting
stress
regulation,
leading
more
precise
treatments
improved
outcomes.
This
review
summarizes
disulfidptosis
mechanisms,
advancements
cancers,
related
response
evaluation,
targeted
therapies,
providing
perspectives
diagnosis
personalized
treatment.
Gut,
Journal Year:
1998,
Volume and Issue:
42(3), P. 442 - 447
Published: March 1, 1998
Background
—Standard
treatment
of
inoperable
hepatocellular
carcinoma
has
not
been
established.
Somatostatin
shown
to
possess
antimitotic
activity
against
a
variety
non-endocrine
tumours.
Aims
—To
assess
the
presence
somatostatin
receptors
in
human
liver
and
treat
advanced
with
analogue,
octreotide.
Methods
—Somatostatin
were
measured
tissue
homogenates
from
patients
acute
chronic
hepatitis,
cirrhosis,
carcinoma.
Fifty
eight
randomised
receive
either
subcutaneous
octreotide
250
μg
twice
daily,
or
no
treatment.
Groups
comparable
respect
age,
sex,
Okuda
classification,
biochemistry
virology.
Results
—Various
amounts
identified
all
including
those
Treated
had
an
increased
median
survival
(13
months
versus
four
months,
p=0.002,
log
rank
test)
cumulative
rate
at
six
12
(75%
37%,
56%
13%
respectively).
Octreotide
administration
significantly
reduced
α
fetoprotein
levels
months.
When
multivariable
Cox’s
proportional
hazards
model
was
fitted,
variables
associated
were:
administration,
absence
serum
albumin,
small
clearly
lower
hazard
(0.383)
multivariate
analysis.
Conclusions
—Octreotide
improves
is
valuable
alternative
Journal of Cancer,
Journal Year:
2024,
Volume and Issue:
15(13), P. 4219 - 4231
Published: Jan. 1, 2024
Hepatocellular
carcinoma
(HCC),
the
predominant
malignancy
of
digestive
tract,
ranks
as
third
most
common
cause
cancer-related
mortality
globally,
significantly
impeding
human
health
and
lifespan.
Emerging
immunotherapeutic
approaches
have
ignited
fresh
optimism
for
patient
outcomes.
This
investigation
probes
link
between
731
immune
cell
phenotypes
HCC
through
Mendelian
Randomization
single-cell
sequencing,
aiming
to
unearth
viable
drug
targets
dissect
HCC's
etiology.
Molecules,
Journal Year:
2024,
Volume and Issue:
29(3), P. 731 - 731
Published: Feb. 5, 2024
The
present
work
aimed
to
study
the
feasibility
of
Angelica
sinensis
polysaccharide
(ASP)
as
an
instinctive
liver
targeting
drug
delivery
carrier
for
oridonin
(ORI)
in
treatment
hepatocellular
carcinoma
(HCC).
ASP
was
reacted
with
deoxycholic
acid
(DOCA)
via
esterification
reaction
form
ASP-DOCA
conjugate.
ORI-loaded
nanoparticles
(ORI/ASP-DOCA
NPs)
were
prepared
by
thin-film
water
method,
and
their
size
about
195
nm
aqueous
solution.
ORI/ASP-DOCA
NPs
had
a
loading
capacity
up
9.2%.
release
ORI
pH-dependent,
resulting
rapid
decomposition
accelerated
at
acidic
pH.
significantly
enhanced
accumulation
tumors
through
ASGPR-mediated
endocytosis.
In
vitro
results
showed
that
increased
cell
uptake
apoptosis
HepG2
cells,
vivo
caused
effective
tumor
suppression
H22
tumor-bearing
mice
compared
free
ORI.
short,
might
be
simple,
feasible,
safe
nano-drug
system
could
used
targeted
tumors.
